Promis Neurosciences (PMN) Competitors $0.42 -0.01 (-2.38%) Closing price 07/7/2025 03:26 PM EasternExtended Trading$0.38 -0.04 (-8.77%) As of 07:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMN vs. ICCC, VHAQ, CLSD, PYRGF, ASRT, ACHL, PDSB, STRO, UNCY, and RPTXShould you be buying Promis Neurosciences stock or one of its competitors? The main competitors of Promis Neurosciences include ImmuCell (ICCC), Viveon Health Acquisition (VHAQ), Clearside Biomedical (CLSD), PyroGenesis Canada (PYRGF), Assertio (ASRT), Achilles Therapeutics (ACHL), PDS Biotechnology (PDSB), Sutro Biopharma (STRO), Unicycive Therapeutics (UNCY), and Repare Therapeutics (RPTX). These companies are all part of the "pharmaceutical products" industry. Promis Neurosciences vs. Its Competitors ImmuCell Viveon Health Acquisition Clearside Biomedical PyroGenesis Canada Assertio Achilles Therapeutics PDS Biotechnology Sutro Biopharma Unicycive Therapeutics Repare Therapeutics ImmuCell (NASDAQ:ICCC) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations. Does the media refer more to ICCC or PMN? In the previous week, ImmuCell had 1 more articles in the media than Promis Neurosciences. MarketBeat recorded 1 mentions for ImmuCell and 0 mentions for Promis Neurosciences. ImmuCell's average media sentiment score of 1.11 beat Promis Neurosciences' score of 0.00 indicating that ImmuCell is being referred to more favorably in the media. Company Overall Sentiment ImmuCell Positive Promis Neurosciences Neutral Which has higher earnings & valuation, ICCC or PMN? Promis Neurosciences has lower revenue, but higher earnings than ImmuCell. ImmuCell is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmuCell$26.49M2.23-$2.16M-$0.07-93.29Promis NeurosciencesN/AN/A$2.78M-$0.05-8.44 Do insiders & institutionals have more ownership in ICCC or PMN? 13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are owned by institutional investors. 6.6% of ImmuCell shares are owned by company insiders. Comparatively, 6.1% of Promis Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend ICCC or PMN? Promis Neurosciences has a consensus target price of $4.50, indicating a potential upside of 966.35%. Given Promis Neurosciences' stronger consensus rating and higher probable upside, analysts clearly believe Promis Neurosciences is more favorable than ImmuCell.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Promis Neurosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ICCC or PMN more profitable? Promis Neurosciences has a net margin of 0.00% compared to ImmuCell's net margin of -1.00%. ImmuCell's return on equity of -1.02% beat Promis Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets ImmuCell-1.00% -1.02% -0.61% Promis Neurosciences N/A -186.19%-98.56% Which has more risk and volatility, ICCC or PMN? ImmuCell has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500. Comparatively, Promis Neurosciences has a beta of -0.1, indicating that its stock price is 110% less volatile than the S&P 500. SummaryPromis Neurosciences beats ImmuCell on 8 of the 15 factors compared between the two stocks. Get Promis Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMN vs. The Competition Export to ExcelMetricPromis NeurosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.13M$2.91B$5.52B$9.02BDividend YieldN/A2.44%5.24%4.05%P/E Ratio-8.4420.4427.2220.08Price / SalesN/A190.25381.5993.26Price / CashN/A41.7026.2128.59Price / Book0.847.397.945.55Net Income$2.78M-$55.04M$3.17B$248.49M7 Day Performance-13.70%2.51%1.79%4.87%1 Month Performance-11.72%-0.21%1.27%6.63%1 Year Performance-78.79%3.41%33.57%20.38% Promis Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMNPromis Neurosciences3.3585 of 5 stars$0.42-2.4%$4.50+966.4%-76.4%$14.13MN/A-8.445Gap UpICCCImmuCell0.2899 of 5 stars$6.62-4.9%N/A+52.6%$62.90M$26.49M-94.5670VHAQViveon Health AcquisitionN/A$11.00flatN/AN/A$62.26MN/A0.002High Trading VolumeCLSDClearside Biomedical1.3953 of 5 stars$0.79-0.9%$4.75+499.1%-36.3%$62.17M$1.66M-1.9330News CoverageGap UpPYRGFPyroGenesis Canada0.0919 of 5 stars$0.33+0.9%N/A-38.7%$62.17M$9.14M-5.5590ASRTAssertio1.6217 of 5 stars$0.64+0.1%$2.75+328.5%-54.4%$61.42M$124.96M-2.0120News CoverageNegative NewsACHLAchilles TherapeuticsN/A$1.48flatN/AN/A$60.83MN/A-0.90250PDSBPDS Biotechnology1.9518 of 5 stars$1.22-8.3%$9.00+637.7%-60.9%$60.79MN/A-1.3020STROSutro Biopharma3.1959 of 5 stars$0.68-4.7%$6.11+799.2%-74.6%$60.30M$62.04M-0.23240UNCYUnicycive Therapeutics3.1364 of 5 stars$4.90+2.7%$60.00+1,124.5%+2.6%$60.30M$680K-0.969High Trading VolumeRPTXRepare Therapeutics2.0649 of 5 stars$1.42+2.2%$4.50+216.9%-55.2%$59.62M$53.48M-0.47180 Related Companies and Tools Related Companies ImmuCell Alternatives Viveon Health Acquisition Alternatives Clearside Biomedical Alternatives PyroGenesis Canada Alternatives Assertio Alternatives Achilles Therapeutics Alternatives PDS Biotechnology Alternatives Sutro Biopharma Alternatives Unicycive Therapeutics Alternatives Repare Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PMN) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Promis Neurosciences Please log in to your account or sign up in order to add this asset to your watchlist. Share Promis Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
